[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN103588672A - Drug for treating cancer pain - Google Patents

Drug for treating cancer pain Download PDF

Info

Publication number
CN103588672A
CN103588672A CN201310537669.XA CN201310537669A CN103588672A CN 103588672 A CN103588672 A CN 103588672A CN 201310537669 A CN201310537669 A CN 201310537669A CN 103588672 A CN103588672 A CN 103588672A
Authority
CN
China
Prior art keywords
pain
cancer
drug
cancer pain
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310537669.XA
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201310537669.XA priority Critical patent/CN103588672A/en
Publication of CN103588672A publication Critical patent/CN103588672A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention belongs to the field of medicine technology, particularly relates to a drug for treating cancer pain, and also relates to a composition containing the drug.

Description

A kind of medicine for the treatment of cancer pain
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of medicine for the treatment of cancer pain.
Background technology
Pain is one of modal Tumor-assaciated symptom, and the definition of pain is " sensation and the emotional experience that are associated with actual or potential tissue injury or similar lesions ".Cancer pain refers to the pain due to cancer, cancer related pathologies and anticancer therapy.Cancer pain is often chronic pain.Pain is cancer patients's common sympton, the cancer patients of approximately 1/4 new diagnosis, 1/3 cancer patients who is receiving treatment and 3/4 patient with advanced cancer merge pain, cancer pain patient may survive several months or several years, if can not get appropriate pain management, patient is by the torment bearing the pain for a long time, and greatly affect their activity, sleep, mood and whole quality of life, pain caused by cancer is patient's personality integrity totteringly, arrange their self consciousness, causing lasting angor in the depth of one's heart.The misery that canurous ache patients is experienced in spirit, social mentality, mode of life, anxiety often surpass the pain that disease itself causes.
The World Health Organization (WHO) organizes palliative treatment expert, cancer pain expert to formulate the global guide of alleviating cancer pain nineteen eighty-two, i.e. famous three step analgesia therapies, although pass by for more than 20 years, the fundamental principle of three ladders is still widely accepted.WHO has determined the international benchmark of the pain therapy centered by opium kind analgesics, becomes the main flow of cancer pain treatment according to the therapeutics of this benchmark.Mild pain: the first ladder of first-selected three ladders be take the NSAID (non-steroidal anti-inflammatory drug) (Nonsteroidal Antiinflammatory Drugs, NSAIDs) that acetylsalicylic acid is representative; Moderate pain: first-selected weak opioid drug (take Cocaine as representative), and can share non-steroidal anti-inflammatory drugs; Severe pain: first-selected strong opioid drug (take morphine as representative), and can share non-steroidal anti-inflammatory drugs simultaneously.But easily there is the side effects such as gastrointestinal damage or renal impairment in known nonopioid analgesic NSAIDs.Also know opium kind analgesics morphine as representational side effect have constipation, feel sick, vomiting etc., also have owing to ending suddenly administration or reducing dosage and bring Withrawal symptom.In addition, in cancer pain, also comprise neuropathic pain, because it is the pain that peripheral nerve or nervus centralis come to harm and occur, so opiates effect is limited.In addition, when morphine chronic administration, the anti-opioid such as cholecystokinin or neuropeptide tyrosine strengthens, and causes the analgesic effect of morphine to decline, and forms analgesia resistance.So need to develop the anodyne of few side effects, replace existing non-opium and opium kind analgesics.
Summary of the invention
The object of the invention is, in order to make up the deficiency of product on market, provides a kind of medicine for the treatment of cancer pain, and chemistry is by name: 7S, and 8R, 17S-trihydroxy--4Z, 9E, 11E, 13Z, 15E, 19Z-bis-dodecahexaenes-N-cyclopropyl amide, structural formula is:
Figure BSA0000097150810000021
A kind of medicine for the treatment of cancer pain of the present invention can be made pharmaceutically acceptable arbitrary formulation with one or more pharmaceutical excipients.
Embodiment
Embodiment 1. is alleviated the evaluation of cancer pain drug effect
Animal modeling: after Animal Anesthesia, left side hind leg cropping, 75% ethanol disinfection femur and shin bone place skin, a skin incision that is about 0.5~1.0cm is cut along rectus femoris muscle tendon direction by knee joint place, the careful kneecap that exposes, first with disposable sterilized 1mL syringe needle, at kneecap, along the puncture of femur long axis direction, punch, then change 10 μ L syringes and enter marrow cavity of femur, slowly inject the Lewis murine lung cancer cell solution of 10 μ L (containing 3 * 10 5individual cell) to femur.After injection, with bone wax seal, live pin hole, clean wound, skin closure.Sham operated rats animal left side kneecap injects isopyknic physiological saline, and all the other operate same model group, and blank group is not carried out any processing.
Evaluation index: measure the thermal stimulus threshold of pain with hot plate method in mice, first that hot plate temperature is constant in (50 ± 1) ℃, then mouse is placed on hot plate, when occurring licking metapedes, needed time value (s) is the threshold of pain of this animal, every mouse is surveyed 3 times, interval 5min, gets 3 averages as the thermal stimulus threshold of pain of this animal (screening Basic Pain Threshold the animal of 10~30s for experiment).
Medication and result: modeling starts administration on the 8th day, is used in conjunction 7d.Modeling the 14th day, the treatment group thermal stimulus threshold of pain obviously extends, and relatively has significant difference (P < 0.05), in Table 1 with model group.
Table 1. pain caused by cancer is respectively organized the variation of the mouse different time points thermal stimulus threshold of pain
Figure BSA0000097150810000022
With model group with time point comparison Δp < 0.05
Conclusion: table 1 data fully show that a kind of medicine for the treatment of cancer pain of the present invention has the effect of good control cancer pain.

Claims (1)

1. treat a medicine for cancer pain, chemistry is by name: 7S, and 8R, 17S-trihydroxy--4Z, 9E, 11E, 13Z, 15E, 19Z-bis-dodecahexaenes-N-cyclopropyl amide, structural formula is:
Figure FSA0000097150800000011
CN201310537669.XA 2013-10-28 2013-10-28 Drug for treating cancer pain Pending CN103588672A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310537669.XA CN103588672A (en) 2013-10-28 2013-10-28 Drug for treating cancer pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310537669.XA CN103588672A (en) 2013-10-28 2013-10-28 Drug for treating cancer pain

Publications (1)

Publication Number Publication Date
CN103588672A true CN103588672A (en) 2014-02-19

Family

ID=50079029

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310537669.XA Pending CN103588672A (en) 2013-10-28 2013-10-28 Drug for treating cancer pain

Country Status (1)

Country Link
CN (1) CN103588672A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160926A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
US10189780B2 (en) 2013-12-12 2019-01-29 Zeno Royalties & Milestones, LLC Bicyclic alkyl compounds and synthesis
US10251851B2 (en) 2013-03-14 2019-04-09 Zeno Royalties & Milestones, LLC Bicyclic analgesic compounds
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
US10975035B2 (en) 2014-09-17 2021-04-13 Recurium Ip Holdings, Llc Bicyclic compounds
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1610542A (en) * 2001-11-23 2005-04-27 阿斯特拉曾尼卡有限公司 New use for the treatment of gastroesophageal reflux disease
WO2006044381A2 (en) * 2004-10-13 2006-04-27 University Of Connecticut Cannabinergic lipid ligands
US20070254862A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
US20120245229A1 (en) * 2009-09-15 2012-09-27 Ru-Rong Ji Method for treating neuropathic pain
CN102725261A (en) * 2009-11-25 2012-10-10 赛托麦蒂克斯有限公司 Arachidonic acid analogs and methods for analgesic treatment using same
CN103254081A (en) * 2013-05-31 2013-08-21 史克勇 Cancer pain therapeutic drug

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1610542A (en) * 2001-11-23 2005-04-27 阿斯特拉曾尼卡有限公司 New use for the treatment of gastroesophageal reflux disease
WO2006044381A2 (en) * 2004-10-13 2006-04-27 University Of Connecticut Cannabinergic lipid ligands
US20070254862A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
US20120245229A1 (en) * 2009-09-15 2012-09-27 Ru-Rong Ji Method for treating neuropathic pain
CN102725261A (en) * 2009-11-25 2012-10-10 赛托麦蒂克斯有限公司 Arachidonic acid analogs and methods for analgesic treatment using same
CN103254081A (en) * 2013-05-31 2013-08-21 史克勇 Cancer pain therapeutic drug

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251851B2 (en) 2013-03-14 2019-04-09 Zeno Royalties & Milestones, LLC Bicyclic analgesic compounds
US10189780B2 (en) 2013-12-12 2019-01-29 Zeno Royalties & Milestones, LLC Bicyclic alkyl compounds and synthesis
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
US10975035B2 (en) 2014-09-17 2021-04-13 Recurium Ip Holdings, Llc Bicyclic compounds
WO2017160926A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds

Similar Documents

Publication Publication Date Title
Monteiro et al. 2022 WSAVA guidelines for the recognition, assessment and treatment of pain
Wenger Anesthesia and analgesia in rabbits and rodents
CN103588672A (en) Drug for treating cancer pain
CN103588668A (en) Compound
Batra et al. Dose response study of caudal neostigmine for postoperative analgesia in paediatric patients undergoing genitourinary surgery
CN103193647A (en) Cancer pain treatment medicine with high optical purity
Shaver et al. A multimodal approach to management of suspected neuropathic pain in a prairie falcon (Falco mexicanus)
Figueiredo et al. Assessment of brachial plexus blockade in chickens by an axillary approach
DeRossi et al. Efficacy of epidural lidocaine combined with tramadol or neostigmine on perineal analgesia in the horse
Stevens et al. Comparison of the effect of intratesticular lidocaine/bupivacaine vs. saline placebo on pain scores and incision site reactions in dogs undergoing routine castration
CN103254077A (en) Pain disease therapeutic agent
CN103393714B (en) Local anaesthetics pain relieving delay agent
CN103193643A (en) Application of Resolvin D1 derivatives in cancer pain
CN103254079A (en) Compounds for treating cancer pains
CN103193646A (en) Medicine for treating pain
CN103254080A (en) Pain therapeutic drug
CN103265432A (en) Drug for treating cancer pain
Kluge et al. Femoral and sciatic nerve blockades and incision site infiltration in rabbits undergoing stifle joint arthrotomy
Isaza et al. Drug delivery to captive Asian elephants-treating Goliath
Bieberly et al. Long-acting injectable methadone (methadone-fluconazole) provides safe and effective postoperative analgesia in a randomized clinical trial for dogs undergoing soft tissue surgery
CN103254081A (en) Cancer pain therapeutic drug
CN103193645A (en) Medicine for treating cancer pain
CN103588671A (en) Medicine for treating cancer pain
CN103588670A (en) Cancer pain medicine
CN103588667A (en) New compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140219